Advances in imaging to support the development of novel therapies for multiple sclerosis

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 4, 2012, Pages 621-634

  Miller, D H ^a   Altmann, D R ^a,b   Chard, D T ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; IMMUNOMODULATING AGENT; N ACETYLASPARTIC ACID; PLACEBO; RADIOLIGAND; SODIUM 23;

ARTICLE; BRAIN ATROPHY; CLINICAL RESEARCH; DIFFUSION TENSOR IMAGING; DISEASE COURSE; GRAY MATTER; HUMAN; IMMUNOMODULATION; LOCOMOTION; LONG TERM CARE; MOLECULAR MECHANICS; MULTIPLE SCLEROSIS; NERVE CELL NETWORK; NERVE FIBER; NERVE REGENERATION; NEUROIMAGING; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RELAPSE; TRACTOGRAPHY;

ANIMALS; DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; OPTIC NEURITIS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84862777007     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.349     Document Type: Article

References (75)

1. Polman, C.H. et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 69, 292-302 (2011).
2. Tintoré, M. et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 67, 968-972 (2006). (Pubitemid 44454586)
3. Fisniku, L.K. et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 131, 808-817 (2008). (Pubitemid 351294716)
4. Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch. Neurol. 65, 727-732 (2008).
5. Tintore, M. et al. Brainstem lesions in clinically isolated syndromes. Neurology 75, 1933-1938 (2010).
6. Swanton, J.K. et al. Early MRI in optic neuritis: the risk for disability. Neurology 72, 542-550 (2009).
7. Kutzelnigg, A. et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128, 2705-2712 (2005). (Pubitemid 41552953)
8. Evangelou, N., Esiri, M.M., Smith, S., Palace, J. & Matthews, P.M. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann. Neurol. 47, 391-395 (2000). (Pubitemid 30141854)
9. Lovas, G., Szilágyi, N., Majtényi, K., Palkovits, M. & Komoly, S. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 123 (Pt 2), 308-317 (2000). (Pubitemid 30055154)
10. Panitch, H., Miller, A., Paty, D. & Weinshenker, B.; North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63, 1788-1795 (2004). (Pubitemid 39532370)
11. Wolinsky, J.S. et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebocontrolled trial. Ann. Neurol. 61, 14-24 (2007). (Pubitemid 46214240)
12. Barkhof, F. et al. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch. Neurol. 60, 1073-1081 (2003). (Pubitemid 36975794)
13. Katz, D., Taubenberger, J.K., Cannella, B., McFarlin, D.E., Raine, C.S. & McFarland, H.F. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann. Neurol. 34, 661-669 (1993). (Pubitemid 23333237)
14. van Walderveen, M.A. et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 50, 1282-1288 (1998). (Pubitemid 28240340)
15. Miller, D.H. et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult. Scler. 14, 1157-1174 (2008).
16. Fisher, J.B. et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 113, 324-332 (2006). (Pubitemid 43170783)
17. Kreisl, W.C. et al. Comparison of [(11)C]-®-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker. Neuroimage 49, 2924-2932 (2010).
18. Owen, D.R. et al. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J. Nucl. Med. 52, 24-32 (2011).
19. Sormani, M.P. et al. Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets. J. Neurol. Neurosurg. Psychiatr. 70, 494-499 (2001). (Pubitemid 32269687)
20. Miller, D.H. et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348, 15-23 (2003). (Pubitemid 36026342)
21. Polman, C.H. et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899-910 (2006).
22. Kappos, L. et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355, 1124-1140 (2006). (Pubitemid 44394919)
23. Kappos, L. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362, 387-401 (2010).
24. O'Connor, P. et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 365, 1293-1303 (2011).
25. CAMMS223 Trial Investigators et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 359, 1786-1801 (2008).
26. Kappos, L. et al. Efficacy and safety of oral fumarate in patients with relapsingremitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372, 1463-1472 (2008).
27. Sormani, M.P., Bonzano, L., Roccatagliata, L., Cutter, G.R., Mancardi, G.L. & Bruzzi, P. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann. Neurol. 65, 268-275 (2009).
28. Moraal, B. et al. Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials. Ann. Neurol. 67, 667-675 (2010).
29. Clifford, D.B. et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 9, 438-446 (2010).
30. Henderson, A.P. et al. A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain 133, 2592-2602 (2010).
31. Henderson, A.P. et al. Early factors associated with axonal loss after optic neuritis. Ann. Neurol. 70, 955-963 (2011).
32. Barkhof, F., Calabresi, P.A., Miller, D.H. & Reingold, S.C. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat. Rev. Neurol. 5, 256-266 (2009).
33. Filippi, M. et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 364, 1489-1496 (2004). (Pubitemid 39410414)
34. Altmann, D.R. et al. Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology 72, 595-601 (2009).
35. Kapoor, R. et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallelgroup trial. Lancet Neurol. 9, 681-688 (2010).
36. Rudick, R.A., Fisher, E., Lee, J.C., Simon, J. & Jacobs, L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53, 1698-1704 (1999). (Pubitemid 29530342)
37. Miller, D.H. et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68, 1390-1401 (2007). (Pubitemid 46659091)
38. Trapp, B.D., Peterson, J., Ransohoff, R.M., Rudick, R., Mörk, S. & Bö, L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278-285 (1998). (Pubitemid 28065253)
39. Molyneux, P.D. et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 123 (Pt 11), 2256-2263 (2000).
40. Chard, D.T., Jackson, J.S., Miller, D.H. & Wheeler-Kingshott, C.A. Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes. J. Magn. Reson. Imaging 32, 223-228 (2010).
41. Fisher, E., Lee, J.C., Nakamura, K. & Rudick, R.A. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann. Neurol. 64, 255-265 (2008).
42. Fisniku, L.K. et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann. Neurol. 64, 247-254 (2008).
43. Furby, J. et al. A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis. J. Neurol. 257, 1508-1516 (2010).
44. Losseff, N.A. et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 119 (Pt 3), 701-708 (1996). (Pubitemid 26237169)
45. Horsfield, M.A. et al. Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: application in multiple sclerosis. Neuroimage 50, 446-455 (2010).
46. van den Elskamp, I.J. et al. Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis. Mult. Scler. 14, 764-769 (2008)
47. Filippi, M., Rovaris, M., Rocca, M.A., Sormani, M.P., Wolinsky, J.S. & Comi, G. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 57, 731-733 (2001). (Pubitemid 32783013)
48. Dalton, C.M. et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J. Neurol. 251, 407-413 (2004). (Pubitemid 38501297)
49. MacManus, D.G. et al. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J. Neurol. 258, 449-456 (2011).
50. Barkhof, F., Hulst, H.E., Drulovic, J., Uitdehaag, B.M., Matsuda, K. & Landin, R. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology 74, 1033-1040 (2010).
51. Ropele, S. et al. MRI assessment of iron deposition in multiple sclerosis. J. Magn. Reson. Imaging 34, 13-21 (2011).
52. De Stefano, N. et al. Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology 69, 1942-1952 (2007). (Pubitemid 350100353)
53. Ciccarelli, O., Catani, M., Johansen-Berg, H., Clark, C. & Thompson, A. Diffusionbased tractography in neurological disorders: concepts, applications, and future developments. Lancet Neurol. 7, 715-727 (2008). (Pubitemid 351957930)
54. Song, S.K., Sun, S.W., Ju, W.K., Lin, S.J., Cross, A.H. & Neufeld, A.H. Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia. Neuroimage 20, 1714-1722 (2003). (Pubitemid 37468277)
55. Schneider, T., Wheeler-Kingshott, C.A. & Alexander, D.C. In-vivo estimates of axonal characteristics using optimized diffusion MRI protocols for single fibre orientation. Med. Image Comput. Comput. Assist. Interv. 13, 623-630 (2010).
56. Mainero, C. et al. In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. Neurology 73, 941-948 (2009).
57. Calabrese, M. et al. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch. Neurol. 64, 1416-1422 (2007). (Pubitemid 47572665)
58. Calabrese, M. et al. The association of intrathecal immunoglobulin synthesis and cortical lesions predicts disease activity in clinically isolated syndrome and early relapsing-remitting multiple sclerosis. Mult. Scler. 18, 174-180 (2012).
59. Agosta, F., Rovaris, M., Pagani, E., Sormani, M.P., Comi, G. & Filippi, M. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain 129, 2620-2627 (2006). (Pubitemid 44522095)
60. Button, T. et al. Magnetisation transfer imaging of alemtuzumab treatment of multiple sclerosis. Ann. Neurol. 17, S437 (2011).
61. Talman, L.S. et al. Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann. Neurol. 67, 749-760 (2010).
62. Schmierer, K., Scaravilli, F., Altmann, D.R., Barker, G.J. & Miller, D.H. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann. Neurol. 56, 407-415 (2004). (Pubitemid 39166560)
63. Chen, J.T., Collins, D.L., Atkins, H.L., Freedman, M.S. & Arnold, D.L.; Canadian MS/BMT Study Group. Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann. Neurol. 63, 254-262 (2008). (Pubitemid 351355304)
64. van den Elskamp, I.J. et al. Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis. Mult. Scler. 16, 660-669 (2010).
65. Laule, C., Kozlowski, P., Leung, E., Li, D.K., Mackay, A.L. & Moore, G.R. Myelin water imaging of multiple sclerosis at 7 T: correlations with histopathology. Neuroimage 40, 1575-1580 (2008).
66. Stankoff, B. et al. Imaging of CNS myelin by positron-emission tomography. Proc. Natl. Acad. Sci. USA 103, 9304-9309 (2006). (Pubitemid 43902573)
67. 1C]-2-(4'- methylaminophenyl)-6-hydroxybenzothiazole. Ann. Neurol. 69, 673-680 (2011).
68. Rocca, M.A. et al. Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurol. 4, 618-626 (2005). (Pubitemid 41317296)
69. Parry, A.M., Scott, R.B., Palace, J., Smith, S. & Matthews, P.M. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain 126, 2750-2760 (2003). (Pubitemid 37463093)
70. Vellinga, M.M. et al. Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. Brain 131, 800-807 (2008). (Pubitemid 351294725)
71. Banati, R.B. et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 123 (Pt 11), 2321-2337 (2000).
72. Srinivasan, R., Sailasuta, N., Hurd, R., Nelson, S. & Pelletier, D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 128, 1016-1025 (2005). (Pubitemid 40675457)
73. Srinivasan, R., Ratiney, H., Hammond-Rosenbluth, K.E., Pelletier, D. & Nelson, S.J. MR spectroscopic imaging of glutathione in the white and gray matter at 7 T with an application to multiple sclerosis. Magn. Reson. Imaging 28, 163-170 (2010).
74. Paling, D., Golay, X., Wheeler-Kingshott, C., Kapoor, R. & Miller, D. Energy failure in multiple sclerosis and its investigation using MR techniques. J. Neurol. 258, 2113-2127 (2011).
75. Inglese, M. et al. Brain tissue sodium concentration in multiple sclerosis: a sodium imaging study at 3 tesla. Brain 133, 847-857 (2010).